Skip to main content
OpenTrials

Clinical trial condition

Parkinson Disease 4, Autosomal Dominant Lewy Body

Explore clinical trials studying Parkinson Disease 4, Autosomal Dominant Lewy Body. Study availability and eligibility vary by location and protocol.

226 public trials 33 recruiting studies
Refine in advanced search Browse all conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body trial results

Completed

Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)

NCT03284424

Conditions
Carcinoma, Carcinoma, Squamous Cell, Neoplasms, +5 more
Locations
  • Moores UC San Diego Cancer Center ( Site 0352) La Jolla, California, United States
  • Stanford University Medical Center ( Site 0366) Palo Alto, California, United States
  • St. Joseph Heritage Healthcare ( Site 0350) Santa Rosa, California, United States
  • Yale University ( Site 0365) New Haven, Connecticut, United States
View all 59 locations
View Trial Details
Completed

Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)

NCT03664024

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +13 more
Locations
  • University Of Colorado ( Site 0908) Aurora, Colorado, United States
  • Harry & Jeanette Weinberg Cancer Institute ( Site 0901) Baltimore, Maryland, United States
  • Henry Ford Health System ( Site 0903) Detroit, Michigan, United States
  • Kingston General Hospital ( Site 0800) Kingston, Ontario, Canada
View all 15 locations
View Trial Details
Completed

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

NCT03950674

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • National Hospital Organization Nagoya Medical Center ( Site 0324) Nagoya, Aichi-ken, Japan
  • Kurume University Hospital ( Site 0326) Kurume, Fukuoka, Japan
  • Hyogo Cancer Center ( Site 0325) Akashi, Hyōgo, Japan
  • Kanazawa University Hospital ( Site 0328) Kanazawa, Ishikawa-ken, Japan
View Trial Details
Completed

Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.

NCT03666273

Conditions
Advanced Solid Tumor, Carcinoma, Carcinoma, Squamous Cell, +8 more
Locations
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • Yale University School of Medicine New Haven, Connecticut, United States
  • University of Chicago Hospitals Chicago, Illinois, United States
  • Henry Ford Health System Detroit, Michigan, United States
View Trial Details

Related conditions